The Clorox Company News
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States. The Household segment provides cat litter products under the Fresh Step and Scoop Away brands; bags and wraps under the Glad brand; and grilling products under the Kingsford brand in the United States. The Lifestyle segment offers dressings, dips, seasonings, and sauces primarily under the Hidden Valley brand; natural personal care products under the Burt's Bees brand; and water-filtration products under the Brita brand in the United States. The International segment provides laundry additives; home care products; water-filtration systems; digestive health products; grilling products; cat litter products; food products; bags and wraps; natural personal care products; and professional cleaning and disinfecting products internationally primarily under the Clorox, Ayudin, Clorinda, Poett, Pine-Sol, Glad, Brita, RenewLife, Ever Clean and Burt's Bees brands. The Clorox Company sells its products primarily through mass retailers; grocery outlets; warehouse clubs; dollar stores; home hardware centers; drug, pet and military stores; third-party and owned e-commerce channels; and distributors, as well as a direct sales force The company was founded in 1913 and is headquartered in Oakland, California.
see moreThe Clorox Company Market News
5d
Clorox Cuts Guidance; Shares Fall to 52-Week Lows!
- Clorox reported mixed results: a modest EPS beat but a lowered full-year guidance that sent CLX shares sharply lower. Rising input costs, integration headwinds and sector-wide pricing pressures are weighing on near-term profit expectations.
12d
Clorox Shock: GOJO Deal, Q2 Hits, Stock Signals #1
Clorox closed its GOJO acquisition while navigating ERP disruption and softer Q2 sales; the stock swung on execution risks, mixed guidance, and defensive sector flows.
19d
Clorox Eyes Growth After GOJO Close; Apr 30 Call
Clorox (CLX) closed its $2.25B GOJO acquisition and set April 30 for Q3 FY2026 results—events that materially shift near-term investor focus toward integration execution, margin recovery, and dividend sustainability.
26d
Clorox After GOJO: Earnings, Yield & Valuation Q3!
Clorox completed the GOJO (Purell) acquisition and will report Q3 FY2026 results on April 30. The deal, recent heavy trading, a near-5% dividend yield, and below-median valuation create a mix of near-term integration risk and longer-term upside potential for CLX investors.
06 Apr at 04:17
Clorox Closes GOJO Deal; Earnings, Dividends React
Clorox completed its acquisition of GOJO (Purell) while reporting mixed Q2 results. Investors responded with elevated trading, a modest stock pullback, and continued interest in Clorox’s attractive dividend. Integration risks, margin volatility, and shifting institutional ownership now shape near-term expectations for CLX.
30 Mar at 04:17
Clorox Faces Margin Squeeze; GOJO Deal May Rescue.
Clorox (CLX) is under pressure from margin compression and shifting consumer choices, prompting analyst downgrades. Recent company updates — an ERP rollout completion, participation at Citi’s consumer conference, and progress on the GOJO (Purell) acquisition with ~$50M expected synergies — outline a path to mid‑term recovery. Key investor watch items are synergy execution, margin inflection, and planned deleveraging from ~3.6× to ~2.5× by 2027.
23 Mar at 04:18
Clorox Faces Downgrade; $2.25B Debt for GOJO
Clorox was downgraded by a major analyst amid margin pressure and weakening demand while recent SEC filings show $2.25 billion in new borrowing to finance the GOJO acquisition. The move raises near-term leverage and execution risks even as hygiene exposure could boost long-term growth.